Last Updated: March 17, 2026 at 6:27 p.m. ET
First Published: March 17, 2026 at 2:28 p.m. ET
In a surprising move, Eli Lilly’s stock has been downgraded by HSBC analysts who argue that the heavily hyped weight-loss-drug market is due for a correction — and that the middle-class Americans who pay out of pocket for these drugs could struggle to do so in the future.
The drugmaker’s stock LLY fell 5.9% on Tuesday, making it the second-worst performer in the S&P 500 SPX.